Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 7/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.34 |
| ▸ | STAMBP | O95630 | 1/20 | 0.34 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.34 |
| ▸ | VNN1 | O95497 | 3/20 | 0.33 |
| ▸ | HPGDS | O60760 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1503085 | 0.80 | NNMT (0.40) | NNMTSMN1; SMN2KDM4EPSMD14STAMBP | |
| SCHEMBL30478243 | 0.80 | NNMT (0.41) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL28285907 | 0.80 | NNMT (0.41) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL28058293 | 0.75 | HPGDS (0.35) | NNMTSMN1; SMN2KDM4EPSMD14STAMBP | |
| SCHEMBL4650847 | 0.74 | NNMT (0.41) | NNMTSMN1; SMN2KDM4EMAPTVNN1 | |
| SCHEMBL30617860 | 0.73 | HPGDS (0.36) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL27688112 | 0.70 | PDK2 (0.41) | KMT2AL3MBTL1 | |
| SCHEMBL28229692 | 0.70 | CYP11B2 (0.45) | KDM4EKMT2A | |
| SCHEMBL28220168 | 0.70 | SYK (0.37) | NNMTSMN1; SMN2KDM4EMAPTKMT2A | |
| SCHEMBL2397267 | 0.70 | NNMT (0.44) | NNMTSMN1; SMN2KDM4EPSMD14STAMBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143408-B2 | N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | claimed |
| EP-2158198-A2 | NOVEL N- (8HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2010-03-03 | — | — | EP | claimed |
| WO-2008130320-A2 | NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | claimed |
| EP-2158198-A2 | NOVEL N- (8HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008130320-A2 | NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |